Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05529251
Other study ID # EDEN (ET21-344)
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 6, 2022
Est. completion date September 6, 2030

Study information

Verified date January 2024
Source Centre Leon Berard
Contact Ellen BLANC
Phone +33 4 78 78 29 67
Email ellen.blanc@lyon.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study. Patients with stage IIa/IIb < 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of Etoposide Cisplatine (EP) chemotherapy. Patients with negative week-3 PET-scan after the EP cycle, will be randomized (1:1 ratio, stratification according to the disease stage (stage IIa versus IIb seminoma)) to receive either radiotherapy (RT) boost on lymph nodes or 1 cycle of carboplatin AUC7 chemotherapy. Patients with positive week-3 PET-scan will received 3 additional cycles of EP chemotherapy. In parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.


Description:

Stage II seminoma is defined by the presence of retroperitoneal lymph node metastases. It concerns approximately 15% of patients with seminoma. The standard treatment for patients with stage IIa/b seminoma, after orchiectomy, is extended lumbo-aortic/ipsilateral iliac radiotherapy (RT). Performing chemotherapy (CT) with 3 courses of Bleomycin-Etoposide-Cisplatin (BEP) or 4 courses of Etoposide-Cisplatin (EP) is an alternative. The optimal treatment choice remains controversial. Both treatment modalities are associated with excellent efficacy but also acute and late toxicities. European Society of Medical Oncology (ESMO) guidelines recommended in equal measure CT and RT for stage IIa. A recent systematic review concluded that RT and cisplatin-based combination CT are equally effective in clinical stage IIa/IIb seminoma, with a trend in favor of chemotherapy in stage IIb because of lower relapse rate. However, due to the rarity of stage II seminoma, a sufficiently powered randomized trial comparing radiotherapy with chemotherapy is unlikely to be completed. De-escalation strategies are required to minimize acute and long-term toxicities while maintaining efficacy. De-escalated treatment for seminoma patients with stage IIb/IIC/III and good prognosis according to International Germ Cell Cancer Collaborative Group (IGCCCG), based on negative PET after 2 cycles of EP chemotherapy, is feasible and safe according to SEMITEP results (cohort 2). In case of negative PET, 1 additional cycle of CT with carboplatin AUC7 was administered. Furthermore, serum levels of microRNA (miR)-371a-3p (miRNA-M371) have been significantly associated with clinical stage, primary tumor size and response to treatment in testicular germ cell tumors, with sensitivity and specificity higher than those of classic markers (hCGt, LDH). However, further evaluations are needed before modifying clinical practices. We propose to conduct a multicenter, prospective, randomized, non-comparative, de-escalation phase II study in patients with stage IIa/IIb seminoma < 3 cm, evaluating: - a more de-escalated CT treatment: 1 cycle of EP followed, in case of negative PET, by either a boost of RT on lymph node or 1 cycle of carboplatin AUC7 - the biomarker miRNA-M371 in therapeutic decision and correlation with PET. In parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date September 6, 2030
Est. primary completion date September 6, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion criteria : 1. Age = 18 years on the day of signing informed consent. 2. Primary testicular seminomatous germ cell tumor. 3. Stage IIa/IIb < 3 cm in largest diameter seminoma, histologically proved after orchiectomy. 4. Confirmation of a progressive disease (positive PET scan or increase of lymph nodes size by two successive CT scan). 5. Good prognosis according to IGCCCG and LDH < 2.5 x Upper Limit of Normal (ULN). 6. Normal alpha-fetoprotein (AFP) before and after orchiectomy. 7. No prior treatment with radiotherapy or chemotherapy. 8. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2. 9. Adequate bone-marrow, hepatic, and renal functions with: - Neutrophils = 1.5 x Giga/l, platelets = 100 x Giga/l, - Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 1,5 x ULN, - Serum creatinine < 140 µmol/l OR calculated clearance > 60 ml/min (using either Cockcroft-Gault formula or Modification of Diet in Renal Disease (MDRD) for > 65 years old), - Direct and total bilirubin = ULN. 10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. 11. Accepting to use effective contraceptive measures or abstain from heterosexual activity, for the course of the study and through 12 months after the last dose of chemotherapy or being surgically sterile. All patients should seek advice regarding cryoconservation of sperm prior treatment initiation because of the possibility of infertility 12. Affiliation to a health insurance. 13. Signed and dated informed consent. Non-exclusion criteria : 1. Extra-retroperitoneal metastasis on Computed tomography scan (CT scan). 2. Infection by Human Immunodeficiency Virus (HIV), or active infection with the Hepatitis B or C virus. 3. History, within 2 years, of cancer other than seminoma, except for treated skin cancer (basal cell). 4. Uncontrolled or severe cardiovascular pathology. 5. Uncontrolled or severe hepatic pathology. 6. Patient deprived of liberty or requiring tutorship or curatorship. 7. Psychological, physical, sociological, or geographical conditions that would limit compliance with study protocol requirements (at the investigator's discretion). 8. Participation to another clinical trial, except for supportive care trials.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Radiotherapy boost
Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week : 20 Gy if no more disease is visible (node < 1 cm in large diameter) 24 Gy for nodes <= 2 cm 30 Gy for nodes > 2 cm
Drug:
Carboplatin AUC7
Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
3 cycles of EP
3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice

Locations

Country Name City State
France CHU Besançon Besançon
France CHU Bordeaux Bordeaux
France Centre François Baclesse Caen
France Centre Jean Perrin Clermont-Ferrand
France Centre Oscar Lambret Lille
France CHU de Limoges Limoges
France Centre Leon Bérard Lyon
France Institut Paoli Calmettes Marseille
France Centre Antoine Lacassagne Nice
France Hôpital Saint Louis Paris
France ICO René Gauducheau Saint-Herblain
France Hôpital Foch Suresnes
France Institut Universitaire de Cancer de Toulouse (IUCT-O) Toulouse
France Institut de Cancérologie de Lorraine Vandœuvre-lès-Nancy
France Institut Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Centre Leon Berard

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary PFR-36M Progression-free rate at 36 months
The PFR-36M is assumed to be a random variable following a binomial distribution Bin (n, p) where n is the sample size and p is the true underlying PFR-36M. Conclusions and inferences will be conducted on p. The prior distribution of p (representing the knowledge of the progression-free rate probability prior to observing the data) will be pre-specified. In the absence of a strong idea about the PFR-36M to be observed, a non-informative prior distribution Beta (1,1) will be considered.
Pr[PFR-36M = 80%] will be expressed in each arm, associated with its 95% credibility interval. A treatment arm will be considered a positive sign for efficacy of de-escalation if there is a high probability that PFR-36M will be higher or equal to 80%: Pr[PFR-36M = 80%] = 90%. It means that if most of the distribution (90% of it) falls to the right hand side of 80%, it indicates that it is very likely that the effect is at least 80%
Up to 36 months after inclusion
Secondary miRNA-M371 Serum level of miRNA-M371 as a potential biomarker of response. Association between serum level of miRNA M371 and response to treatments (according to RECIST v1.1) will be evaluated using a non-parametric Wilcoxon Mann and Whitney test and describe with boxplots. Up to 5 years
Secondary Association of PET scan results and miRNA-M371 rate Correlation between serum level of miRNA M371 and FDG-PET results (metabolic response) will be evaluated using the Kendall rank correlation and describe graphically. Up to 5 years
Secondary Overall survival (OS) The Overall Survival will be defined as the time from date of inclusion to the date of death, from any cause. Patient whose death is not known at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.
The Kaplan-Meier (KM) approach will be used to estimate median OS. Median OS as well as Survival rates at specific timepoints will be presented together with their 95% confidence interval (CI).
Up to 3 years
Secondary Quality of life (QoL) The QoL will be assessed using the EORTC QLQ-C30 questionnaire. Up to 20 months
Secondary Tolerance to treatment The tolerance to each treatment will be described mainly on the frequency of adverse events (AEs) and their intensity and severity determined using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale version 5. Descriptive statistics will be provided for characterizing and assessing patient tolerance to treatment.
AEs will be described and coded, in total and per System Organ Class and Preferred Term with Medical Dictionary for Regulatory Activities (MedDRA) coding
Up 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT06133543 - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer N/A
Completed NCT00705094 - Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients N/A
Active, not recruiting NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Phase 2
Recruiting NCT01887340 - Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma Phase 2
Active, not recruiting NCT01593241 - Therapy De-escalation in Seminoma Stage IIA/B Phase 2
Recruiting NCT04876456 - A Phase II Trial of Cabozantinib With Patients With Refractory GCTs Phase 2
Active, not recruiting NCT03937843 - Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma Phase 2
Recruiting NCT04435756 - A Study of miRNA 371 in Patients With Germ Cell Tumors
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT06309745 - THERApy De-escalation for TESTicular Cancer
Recruiting NCT04914026 - MicroRNA as Markers in Testicular Cancer
Not yet recruiting NCT05142982 - Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma N/A
Active, not recruiting NCT02375204 - Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Phase 3
Recruiting NCT06144736 - PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND Phase 2
Recruiting NCT02341989 - Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer Phase 3